These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 18809819)
81. Analysis and optimal control of an HIV model based on CD4 count. Ishaku A; Gazali AM; Abdullahi SA; Hussaini N J Math Biol; 2020 Jul; 81(1):209-241. PubMed ID: 32601724 [TBL] [Abstract][Full Text] [Related]
82. A 10-year economic analysis of HIV management in Greece: evidence of efficient resource allocation. Athanasakis K; Naoum V; Naoum P; Nomikos N; Theodoratou D; Kyriopoulos J Curr Med Res Opin; 2022 Feb; 38(2):265-271. PubMed ID: 34873979 [TBL] [Abstract][Full Text] [Related]
83. The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. Krentz HB; Gill MJ AIDS Res Treat; 2012; 2012():757135. PubMed ID: 21904673 [TBL] [Abstract][Full Text] [Related]
84. The impact of near-patient testing on the organisation and costs of an anticonvulsant clinic. Elliot K; Watson ID; Tsintis P; Gray J; Stewart MJ; Kadr H; Lawson DH Ther Drug Monit; 1990 Sep; 12(5):434-7. PubMed ID: 2293404 [TBL] [Abstract][Full Text] [Related]
85. SMARThivCD4mos: a complexity-free and cost effective model technology for monitoring HIV patients CD4 number in resource-poor settings. Yari A; Passo FS; Yari V; Sanni O; Yari M; Dovenou MZ; Traore R; Hounyet JP Bioinformation; 2008 Jan; 2(6):257-9. PubMed ID: 18317577 [TBL] [Abstract][Full Text] [Related]
86. Systematic Review of Methods to Determine the Cost-Effectiveness of Monitoring Plans for Chemical and Biological Hazards in the Life Sciences. Focker MM; van der Fels-Klerx HJI; Oude Lansink AGJMA Compr Rev Food Sci Food Saf; 2018 May; 17(3):633-645. PubMed ID: 33350127 [TBL] [Abstract][Full Text] [Related]
87. SMARThivPack: a complexity free and cost effective "three tests" combo kit model for improving HIV patients monitoring standards in resource poor settings. Yari A; Passo FS; Hounyet JP Bioinformation; 2007 Dec; 2(3):97-100. PubMed ID: 18288332 [TBL] [Abstract][Full Text] [Related]
88. State-of-the-Art Molecular Oncology in Brazil. Rodrigues T Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298404 [TBL] [Abstract][Full Text] [Related]
89. 'What about the carbon?' A call to count carbon costs prospectively to count carbon costs and savings in healthcare models. Pearn L; Auret K; Pikora T Intern Med J; 2022 Nov; 52(11):2013. PubMed ID: 36404116 [No Abstract] [Full Text] [Related]
91. HIV-1/HBV Coinfection Accurate Multitarget Prediction Using a Graph Neural Network-Based Ensemble Predicting Model. Wang Y; Li Y; Chen X; Zhao L Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108305 [TBL] [Abstract][Full Text] [Related]
92. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Zaongo SD; Ouyang J; Chen Y; Jiao YM; Wu H; Chen Y Front Immunol; 2022; 13():853346. PubMed ID: 35432307 [TBL] [Abstract][Full Text] [Related]
93. Stepped care for depression at integrated chronic care centers (IC3) in Malawi: study protocol for a stepped-wedge cluster randomized controlled trial. McBain RK; Mwale O; Ruderman T; Kayira W; Connolly E; Chalamanda M; Kachimanga C; Khongo BD; Wilson J; Wroe E; Raviola G; Smith S; Coleman S; Kelly K; Houde A; Tebeka MG; Watson S; Kulisewa K; Udedi M; Wagner G Trials; 2021 Sep; 22(1):630. PubMed ID: 34530894 [TBL] [Abstract][Full Text] [Related]
94. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis. Bernard CL; Rao IJ; Robison KK; Brandeau ML PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929 [TBL] [Abstract][Full Text] [Related]
95. Health outcomes and cost-effectiveness of treating depression in people with HIV in Sub-Saharan Africa: a model-based analysis. Zhong H; Arjmand IK; Brandeau ML; Bendavid E AIDS Care; 2021 Apr; 33(4):441-447. PubMed ID: 31986900 [TBL] [Abstract][Full Text] [Related]
96. Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response. Drain PK; Dorward J; Bender A; Lillis L; Marinucci F; Sacks J; Bershteyn A; Boyle DS; Posner JD; Garrett N Clin Microbiol Rev; 2019 Jun; 32(3):. PubMed ID: 31092508 [TBL] [Abstract][Full Text] [Related]
97. HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing? Neilan AM; Cohn JE; Lemaire JF; Sacks E; Alban R; Freedberg KA; Walensky RP; Ciaranello AL Open Forum Infect Dis; 2018 Aug; 5(8):ofy170. PubMed ID: 30182030 [TBL] [Abstract][Full Text] [Related]
98. Structural Sensitivity in HIV Modeling: A Case Study of Vaccination. Bernard CL; Brandeau ML Infect Dis Model; 2017 Nov; 2(4):399-411. PubMed ID: 29532039 [TBL] [Abstract][Full Text] [Related]
99. Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review. Barnabas RV; Revill P; Tan N; Phillips A J Int AIDS Soc; 2017 Nov; 20 Suppl 7(Suppl 7):. PubMed ID: 29171172 [TBL] [Abstract][Full Text] [Related]